Loading people...
Jonathan Waldstreicher is a Partner at Apple Tree Partners based in New York, New York. Before joining the life sciences venture capital firm in 2013, he served as Director of Global Surgery R&D at Johnson & Johnson and previously worked in equity research at Bear Stearns. As a physician-investor, he founded and served as the initial CEO of Galvanize Therapeutics, where he executed a $100 million venture financing round in September 2022 to consolidate three distinct medical device startups. Under his operational leadership, the consolidated company secured FDA 510(k) clearance for its pulsed electric field system in August 2023, building upon his clinical foundation that includes an MD and MBA from Tufts University and a BA from Brandeis University. Waldstreicher currently focuses on creating, incubating, and scaling early-stage medical device and therapeutics portfolio companies.
Jonathan Waldstreicher stands as a key figure in the vibrant world of life sciences venture capital, serving as a highly respected Partner at ATP (Apple Tree Partners). ATP is renowned for its unique approach to company creation and investment, focusing exclusively on groundbreaking opportunities within the life sciences sector, particularly biotechnology and pharmaceuticals. As a Partner, Jonathan Waldstreicher is instrumental in shaping the firm's investment strategy, identifying promising scientific innovations, and guiding the development of new therapeutic entities.
At ATP, Jonathan Waldstreicher's role encompasses a broad range of responsibilities, from rigorous due diligence on potential investments to active participation in the strategic direction of portfolio companies. His work is critical in evaluating novel drug candidates, assessing market potential, and building robust management teams capable of translating scientific discoveries into impactful medicines. The firm's model often involves incubating companies from inception, providing not just capital but also deep operational expertise, a process in which Jonathan Waldstreicher's insights are invaluable.
Jonathan Waldstreicher's investment focus aligns perfectly with ATP's mission: to create and invest in companies that are developing transformative therapies for significant unmet medical needs. This typically includes areas such as oncology, immunology, neurology, rare diseases, and other therapeutic domains where innovative science can lead to significant patient benefit. His expertise helps ATP navigate the complex landscape of drug discovery and development, from preclinical research through clinical trials and commercialization strategies.
While specific details of Jonathan Waldstreicher's career background are extensive, his trajectory likely reflects a strong foundation in scientific research, medicine, or the pharmaceutical industry. Professionals in his position at leading life sciences venture firms often possess advanced degrees (such as an MD or PhD) and prior experience in drug development, clinical practice, or scientific leadership roles. This deep understanding of both the science and the business of healthcare is what enables him to identify truly disruptive technologies and guide them towards success. His contributions are vital to ATP's track record of fostering companies that have brought important new treatments to patients worldwide.
Through his strategic leadership and discerning investment choices, Jonathan Waldstreicher plays a significant role in advancing medical innovation. He is a driving force behind ATP's commitment to building companies that not only generate strong returns but also make a profound positive impact on global health.
Jonathan Waldstreicher is a distinguished Partner at ATP (Apple Tree Partners), a leading venture capital firm focused on the life sciences sector, particularly biotechnology and pharmaceuticals.
Jonathan Waldstreicher invests in groundbreaking opportunities within the life sciences, including biotechnology and pharmaceutical companies. His focus is on developing transformative therapies for significant unmet medical needs across various therapeutic areas.
Jonathan Waldstreicher works as a Partner at ATP (Apple Tree Partners), a premier venture capital firm specializing in creating and investing in life sciences companies.
